Alnylam Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Alnylam Pharmaceuticals Inc.
Vanguard Health Care Fund
7,782,825
7.73%
893,408
1.9%
06/30/2018
Fidelity Growth Company Fund
5,055,245
5.01%
-27,429
1.28%
07/31/2018
Dodge & Cox Stock Fund
2,813,861
2.8%
0
0.46%
06/30/2018
Vanguard Total Stock Market Index Fund
2,272,798
2.25%
9,114
0.04%
07/31/2018
Vanguard Mid Cap Index Fund
2,147,154
2.13%
16,889
0.26%
07/31/2018
T Rowe Price Mid Cap Growth Fund
1,700,000
1.69%
-50,000
0.63%
06/30/2018
Fidelity Select Biotechnology Portfolio
1,485,678
1.48%
0
1.98%
07/31/2018
Fidelity Series Growth Company Fund
1,419,923
1.41%
0
1.3%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,161,959
1.14%
-15,204
1.46%
09/06/2018
Vanguard Extended Market Index Fund
1,106,380
1.1%
1,305
0.19%
07/31/2018
| Address |
300 Third Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.alnylam.com |
| Updated |
07/08/2019 |
| Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. |
